Valuation: Denali Therapeutics Inc.

Market Cap 3.35B 2.95B 2.79B 2.53B 4.75B 322B 4.78B 33.39B 12.9B 164B 12.59B 12.32B 528B P/E 2026 *
-9.07x
P/E 2027 * -9.15x
Enterprise Value 2.65B 2.33B 2.2B 2B 3.75B 254B 3.77B 26.34B 10.17B 130B 9.93B 9.72B 416B EV / Sales 2026 *
52.3x
EV / Sales 2027 * 20.1x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day+2.89%
1 week+2.49%
Current month-11.70%
1 month-12.58%
3 months-17.95%
6 months+15.53%
Current year+27.07%
1 week 19.72
Extreme 19.725
21.51
1 month 19.4
Extreme 19.4
24.01
Current year 15.34
Extreme 15.34
27.3
1 year 13.75
Extreme 13.75
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
56.08
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 01/05/2022
Chief Executive Officer 50 01/08/2015
Chief Tech/Sci/R&D Officer 58 06/11/2025
Director TitleAgeSince
Director/Board Member 50 01/03/2015
Director/Board Member 73 01/04/2015
Director/Board Member 68 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/26 Sell

Chief Technology Officer

-1,654 0.0010%
2/9/26 Sell

Director

-11,439 0.0072%
1/9/26 Sell

Founder

-2,768 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
+2.89%+2.49%+50.39%+0.10% 3.26B
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-2.70%+37.74%+86.90% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
-0.14%-2.75%-14.13%+356.79% 25.73B
+0.57%+1.10%+1.02%-2.89% 24.75B
+1.10%+1.86%+25.07%-8.51% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%+2.01%+49.51%+160.70% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average +0.09%-0.24%+38.74%+149.00% 27.84B
Weighted average by Cap. -0.09%-0.73%+38.28%+124.60%

Financials

2026 *2027 *
Net sales 50.57M 44.48M 42.06M 38.15M 71.64M 4.85B 72.06M 504M 194M 2.48B 190M 186M 7.96B 130M 114M 108M 97.7M 183M 12.43B 185M 1.29B 498M 6.34B 486M 476M 20.39B
Net income -454M -399M -377M -342M -643M -43.55B -646M -4.52B -1.74B -22.22B -1.7B -1.67B -71.4B -449M -395M -374M -339M -637M -43.14B -640M -4.48B -1.73B -22.01B -1.69B -1.65B -70.74B
Net Debt -708M -623M -589M -534M -1B -68B -1.01B -7.05B -2.72B -34.7B -2.66B -2.6B -112B -749M -658M -623M -565M -1.06B -71.87B -1.07B -7.46B -2.88B -36.67B -2.81B -2.75B -118B
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
503
Date Price Change Volume
28/09/26 USD 20.98 +2.89% 2,559,526
25/09/26 USD 20.39 -0.39% 1,257,680
24/09/26 USD 20.47 +0.05% 2,273,111
23/09/26 USD 20.46 -5.28% 1,914,176
22/09/26 USD 21.60 +5.52% 2,336,642
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
20.98USD
Average target price
36.06USD
Spread / Average Target
+71.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DNLI Stock